| Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma J Svoboda, SR Rheingold, SI Gill, SA Grupp, SF Lacey, I Kulikovskaya, ... Blood, The Journal of the American Society of Hematology 132 (10), 1022-1026, 2018 | 73 | 2018 |
| Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas J Svoboda, SM Bair, DJ Landsburg, SD Nasta, SJ Nagle, SK Barta, ... Haematologica 106 (6), 1705, 2021 | 53 | 2021 |
| Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis SM Bair, LE Strelec, TA Feldman, G Ahmed, P Armand, NN Shah, ... The Oncologist 24 (7), 955-962, 2019 | 34 | 2019 |
| Pilot study of non-viral, RNA-redirected autologous anti-CD19 chimeric antigen receptor modified T-cells in patients with refractory/relapsed Hodgkin lymphoma (HL) J Svoboda, SR Rheingold, SI Gill, SA Grupp, SF Lacey, JJ Melenhorst, ... Blood 130, 653, 2017 | 8 | 2017 |
| Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas J Svoboda, SM Bair, C Steidl, M Ruella, DJ Landsburg, SD Nasta, ... Blood 132, 2959, 2018 | 1 | 2018 |
| Clinical Outcomes of Anti PD-1 Immunotherapy in Patients with Relapsed/Refractory Non Hodgkin Lymphomas ME Hughes, C Jensen, J Svoboda, LE Strelec, MR Youngman, ... Blood 130, 1575, 2017 | | 2017 |
| Outcomes, Toxicities, and Patterns of Use of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Multicenter Retrospective Study SM Bair, LE Strelec, TA Feldman, NN Shah, N Reddy, N Khan, ... Blood 130, 4091, 2017 | | 2017 |
